Search Within

Charles Ryan

  1. "Biostatistics Service"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Biostatistics Service (6)
  2. Department of Medicine (6)
  3. Epidemiology and Biostatistics (6)
  4. Genitourinary Oncology Service (6)
  5. Solid Tumor Oncology Division (6)
  6. Department of Pathology and Laboratory Medicine (4)

More Groups

People
  1. Howard Scher (6)
  2. Alexander Smith (4)
  3. Jaya Satagopan (4)
  4. Peter Scardino (4)
  5. Priti Lal (4)
  6. Victor Reuter (4)

More People

Years
  1. 2007 (1)
  2. 2006 (1)
  3. 2004 (2)
  4. 2003 (2)
Publications
  1. Urology (2)
  2. American Journal of Pathology (1)
  3. Journal of Urology (1)
  4. Laboratory Investigation (1)
  5. Modern Pathology (1)
Publishers
  1. Elsevier Science, Inc. (4)
  2. Nature Publishing Group (1)
  3. Nature Research (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression
    Journal Article

    Ryan, C. J.; Smith, A.; Lal, P.; Satagopan, J.; Reuter, V.; Scardino, P.; Gerald, W.; Scher, H. I.
    Urology (2006)

    Fulltext@MSK | Save
  • Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Journal Article

    Holzbeierlein, J.; Lal, P.; LaTulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P.; more...
    American Journal of Pathology (2004)

    Fulltext@MSK | Save
  • Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Journal Article

    Ryan, C. J.; Zelefsky, M. J.; Heller, G.; Regan, K.; Leibel, S. A.; Scher, H. I.; Kelly, W. K.
    Urology (2004)

    Fulltext@MSK | Save
  • Transcriptional programs affected by androgen ablation therapy and the development of therapy resistant prostate cancer
    Meeting Abstract

    Lal, P.; Holzbeierlein, J.; LaTulippe, E.; Satagopan, J.; Smith, A.; Ryan, C.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.
    Laboratory Investigation (2003)

    Fulltext@MSK | Save
  • Transcriptional programs affected by androgen ablation therapy and the development of therapy resistant prostate cancer
    Meeting Abstract

    Lal, P.; Holzbeierlein, J.; LaTulippe, E.; Satagopan, J.; Smith, A.; Ryan, C.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.
    Modern Pathology (2003)

    Fulltext@MSK | Save